Study of treatments for liver scarring from fatty liver disease
Part of Digestive system, Hormones & metabolism clinical trials.
This study is testing ways to prevent and treat liver scarring (fibrosis) caused by a condition called MAFLD, which is a buildup of fat in the liver. If you have this condition and some liver scarring, this trial may offer a chance to help manage it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with MAFLD (fatty liver disease).
- A liver biopsy within the last 6 months shows stage F0 to F4 scarring.
- Your liver scarring is not due to other causes like heavy alcohol use, hepatitis B or C, or certain medications.
- You agree to sign a consent form.
- You have not had heavy drinking in the past year.
- You have not taken certain medications known to harm the liver for more than 2 weeks in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This study tests whether a diabetes medicine called henagliflozin can reduce liver scarring in people who have both fatty liver disease (MASLD) and type 2 diabetes. If you qualify, you may receive the study drug and help researchers learn if it can improve liver health.
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
This study tests whether taking rezdiffra (a liver medication) together with other common diabetes or liver drugs is safe and effective for adults with MASH (fatty liver disease) and moderate-to-severe liver scarring. It may help improve liver health and reduce disease progression.
Hear when a new Metabolic Dysfunction-associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.